Kura Oncology (NASDAQ:KURA) Shares Up 4.1% - Should You Buy?

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) rose 4.1% on Thursday . The stock traded as high as $7.47 and last traded at $7.57. Approximately 30,728 shares traded hands during trading, a decline of 97% from the average daily volume of 1,051,821 shares. The stock had previously closed at $7.27.

Analyst Upgrades and Downgrades

Several research analysts have commented on KURA shares. StockNews.com lowered Kura Oncology from a "buy" rating to a "hold" rating in a research report on Tuesday, March 18th. Wedbush reissued an "outperform" rating and set a $36.00 price target on shares of Kura Oncology in a report on Thursday, February 27th. BTIG Research downgraded Kura Oncology from a "buy" rating to a "neutral" rating in a research note on Thursday, February 6th. Cantor Fitzgerald upgraded Kura Oncology to a "strong-buy" rating in a research note on Tuesday, March 4th. Finally, JMP Securities reissued a "market outperform" rating and issued a $28.00 target price on shares of Kura Oncology in a report on Thursday, February 6th. Four analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $25.50.

Remove Ads

Kura Oncology Trading Down 4.5 %

The firm's fifty day moving average price is $7.82 and its 200-day moving average price is $12.38. The company has a market cap of $604.85 million, a price-to-earnings ratio of -3.17 and a beta of 0.85. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47.

Kura Oncology (NASDAQ:KURA - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.43. The company had revenue of $53.88 million during the quarter, compared to the consensus estimate of $57.96 million. On average, equities analysts expect that Kura Oncology, Inc. will post -2.44 EPS for the current fiscal year.

Insider Transactions at Kura Oncology

In other news, insider Mollie Leoni sold 4,963 shares of the company's stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the transaction, the insider now directly owns 88,253 shares of the company's stock, valued at approximately $694,551.11. This represents a 5.32 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Thomas James Doyle sold 4,949 shares of the firm's stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the transaction, the senior vice president now owns 88,193 shares in the company, valued at approximately $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 11,729 shares of company stock valued at $92,307 over the last ninety days. Corporate insiders own 5.50% of the company's stock.

Institutional Investors Weigh In On Kura Oncology

A number of institutional investors have recently bought and sold shares of the business. Virtus ETF Advisers LLC lifted its stake in Kura Oncology by 71.6% during the fourth quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company's stock worth $64,000 after purchasing an additional 3,061 shares during the period. Harbor Advisors LLC acquired a new position in shares of Kura Oncology in the 4th quarter worth approximately $87,000. E Fund Management Co. Ltd. bought a new position in shares of Kura Oncology during the 4th quarter worth approximately $90,000. Corton Capital Inc. acquired a new stake in Kura Oncology in the 4th quarter valued at $99,000. Finally, Optimize Financial Inc bought a new position in shares of Kura Oncology during the fourth quarter valued at $100,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.